Peripheral Artery Disease

Peripheral artery disease (PAD) involves atherosclerosis mainly in the extremities, especially in the legs and feet that lead to ischemia. Untreated, PAD can progress to critical limb ischemia (CLI), also called chronic limb-threatening ischemia (CLTI), which will lead to foot or leg amputation. The mortality rate for these CLI amputees is 70% within three years. There is currently an epidemic of PAD and CLI in the U.S. The majority of patients are defined by health disparities concentrated in the Black, Latino, Native American populations in both rural and low-income urban areas. A large number of PAD patients have other comorbities, with diabetes being one a primary issue.

New guidelines help interventional cardiologists manage chronic venous disease
"These recommendations will help ensure that patient care remains both consistent and personalized," SCAI President Srihari S. Naidu, MD, explained.
Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease
Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.
New-look peripheral stent with expandable spikes receives FDA’s de novo classification
California-based Reflow Medical gained the approval after submitting data from the DEEPER REVEAL clinical trial. The device was associated with a high success rate and improved outcomes in CLTI patients.
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Multimodality imaging uncovers ‘landmarks’ for peripheral arterial disease recovery

These new recovery milestones will allow clinicians to pinpoint whether or not a patient is responding to therapy or making the necessary strides toward rehabilitation.

Endovascular-first approach boosts amputation-free survival in patients with critical limb ischemia

Patients with critical limb ischemia might be better off if they opt for endovascular-first treatment over an open surgical bypass, a Circulation: Cardiovascular Quality and Outcomes study suggests.

New data from the IMPERIAL clinical program demonstrates ELUVIA more effective in diabetic patients

LEIPZIG and MARLBOROUGH, Mass. (January 22, 2019) — Boston Scientific (NYSE: BSX) today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically significant lower rates of target lesion revascularization (TLR) and stent thrombosis when compared to those treated with the Zilver® PTX® Drug-Eluting Peripheral Stent.

Appropriate use criteria give edge to endovascular therapies for treating PAD

Several professional societies collaborated to release appropriate use criteria for peripheral artery intervention (PAI), a field the authors acknowledged still has an emerging evidence base that is likely to change these recommendations in the future.

CLI revascularization techniques are more cost-effective, associated with longer survival than amputation

Revascularization techniques to treat primary critical limb ischemia (CLI) may be more cost-effective and associated with longer survival than primary major amputation, according to new research published in the Journal of the American Heart Association.

USPSTF: Evidence insufficient to assess benefits, harms of using ABI to screen for PAD

The U.S. Preventive Services Task Force (USPSTF) issued a Grade I recommendation for screening peripheral artery disease (PAD) and cardiovascular disease (CVD) risk with the ankle-brachial index (ABI), indicating current evidence is insufficient to recommend screening without signs or symptoms of disease.

FDA approves more lengths of Medtronic’s drug-coated balloon for PAD

The 200 and 250 millimeter lengths of Medtronic’s IN.PACT Admiral drug-coated balloon gained FDA approval to treat long superficial artery (SFA) lesions in patients with peripheral artery disease (PAD), the company announced June 15.

Exercise interventions for PAD may require personal support

A randomized trial published April 24 in JAMA suggests patients with lower-extremity peripheral artery disease (PAD) can’t be expected to improve walking performance on their own, even with the aid of wearable activity trackers and telephone coaching sessions.

Peripheral Artery Disease

New guidelines help interventional cardiologists manage chronic venous disease

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

New-look peripheral stent with expandable spikes receives FDA’s de novo classification

Late-breaking cardiovascular drug trials took center stage at ACC.25

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes